Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1C03XA01----2件: 67, 72
2Desmopressin1件: Desmopressin1件: D00291 2件: AVPR2,
F8 💬
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬5件: 6, 64, 72, 225, 288
3Desmopressin intranasal1件: Desmopressin1件: D00291 2件: AVPR2,
F8 💬
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
4Desmopressin Oral Melt1件: Desmopressin1件: D00291 2件: AVPR2,
F8 💬
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
5Empagliflozin1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-6件: 58, 65, 67, 72, 97, 257
6Empagliflozin 25 MG1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-1件: 72
7Empagliflozin 25mg1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-1件: 72
8Empagliflozin 25mg Tbl1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-1件: 72
9EXENATIDE1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬6件: 6, 17, 72, 78, 193, 233
10Experimental: CRH administration----2件: 72, 78
11Experimental: GLP1-RA (exenatide) administration1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬2件: 72, 78
12IUPAC----1件: 72
13Melatonin1件: Melatonin1件: D08170 2件: MTNR1A,
MTNR1B 💬
2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬12件: 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
14Oxytocin1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬7件: 6, 72, 127, 168, 193, 206, 226
15Oxytocin nasal spray1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬2件: 72, 193
16Samsca1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬2件: 67, 72
17SAMSCA*10CPR 15MG1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
18Satavaptan1件: Satavaptan---1件: 72
19Satavaptan (SR121463)1件: Satavaptan---1件: 72
20Satavaptan (SR121463B)1件: Satavaptan---1件: 72
21SR121463B----1件: 72
22TOLVAPTAN1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬4件: 67, 72, 86, 225
23Tolvaptan (SAMSCA)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
24Tolvaptan in euvolemic hyponatremia1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
25Tolvaptan Oral Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 72
26Urea1件: Urea2件: D00023 ,
D01749
--2件: 72, 251